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Abstract: Takayasu arteritis (TAK) is a challenging chronic, granulomatous, large-vessel systemic vasculitis, mostly due to difficulties in
early diagnosis and assessing actual disease activity. Since there are no specific diagnostic laboratory tests, biomarkers, or autoantibodies,
many patients experience considerable delay in diagnosis. Remembering the possibility of TAK together with the use of acute phase
responses and appropriate imaging studies may be helpful for early diagnosis. Since there may be discrepancies between systemic and
vascular wall inflammation, using only acute phase responses is not reliable in assessing current disease activity. Therefore, physical
examination and new imaging findings should also be used to assess current disease activity. Despite its limitations, the Indian Takayasu
Clinical Activity Score (ITAS2010) may also be helpful for this purpose. The rationale of medical treatment is to suppress both vascular and
systemic inflammation with appropriate systemic immunosuppression, including corticosteroids and conventional immunosuppressive
agents. In cases of refractory disease activity, leflunomide and biologic agents such as TNF inhibitors and tocilizumab may be tried.
In selected cases with persistent lesions that cannot be reversed with medical treatment, endovascular interventions including balloon
angioplasty, stent and stent graft replacement, or surgery may be tried. However, such procedures should be performed after suppression
of inflammation, i.e. during inactive disease. Prognosis of TAK is probably getting better with lower mortality rates reported in recent
years, probably due to the use of more effective medical treatments as well as the use of endovascular interventions when necessary and
available.
Key words: Takayasu arteritis, large vessel vasculitis, management, diagnosis, disease activity

1. Introduction
Definition, basic concepts, and epidemiology of Takayasu
arteritis Takayasu arteritis (TAK), also known as
“pulseless disease”, “aortic arch syndrome”, or “occlusive
thromboarthropathy”, was first described by Mikito
Takayasu, a professor of ophthalmology at Kanazawa
University in Japan, as a case of retinal vasculitis with
pulselessness in 1908 (1). TAK is a chronic, granulomatous,
large-vessel vasculitis, characterized by stenosis, occlusion,
and sometimes aneurysm of the aorta and its main branches,
especially of the subclavian, common, and internal carotid
arteries. However, other large vessels including pulmonary
arteries, as well as medium-sized coronary arteries, may
also be involved (2,3). The clinical picture varies based
on the arteries involved and the severity of inflammation.
TAK generally follows an insidious course at onset, but
presentation with atypical and/or catastrophic disease,
such as with acute visual loss or stroke, may also occur
(4,5). Unfortunately many patients experience considerable
delay in diagnosis since there are no specific diagnostic
laboratory tests, biomarkers, or autoantibodies (2,6).

TAK occurs more commonly in young females,
generally in those less than 40 years of age, although
it may also be seen in older patients (7). TAK is present
more often in Far Eastern and Asian countries, while it is
relatively uncommon in northern European and American
countries (7,8). Ethnicity is an important factor not only
for the frequency of TAK, but also for the severity and the
prognosis of the disease. While a Japanese nation-wide
registry reported at least 5881 TAK patients in Japan in
2011 with a prevalence higher than 4/million (8), only 197
patients from seven Arab countries with a total population
of approximately 80 million could be enrolled in a recent
study (9). In a population-based study performed in
the United Kingdom, Watts et al. found that the overall
annual incidence of TAK was 0.8/million, while the mean
prevalence was 4.7/million (7).
In Turkey, it is presumed to be the second most
frequent systemic vasculitis seen in the adult population,
after Behçet’s disease. Recently, Birlik et al. investigated
the prevalence and incidence of TAK among the residents
of the city of İzmir, which is the third largest metropolis
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in Turkey, located in the Aegean region (10). The annual
prevalence was estimated as 12.8/million in the total
population and 23.5/million in females. The prevalence
was higher than 8.8/million in the population >40
years of age. During the study period, the mean annual
incidence of TAK was estimated as 1.11/million (10).
In another study conducted in the northwestern part of
Turkey, the annual incidence rate for TAK was found to be
0.34/100,000, while the overall prevalence was 3.3/100,000
in individuals >16 years of age. The authors concluded that
in the northwestern part of Turkey the annual incidence
and prevalence of TAK were higher than in the western
population, but similar to East Asian data (11).
In a comparative study from France investigating TAK
among white, North African, and black patients, median
age at diagnosis was 39.3 years in white, 28.4 years in
North African, and 28.0 years in black patients (12). North
African patients had more frequent relapses of ischemic
strokes and poorer survival than whites. The 5- and 10year survival rates were 100% and 95.0%, respectively, in
whites; 100% at both 5 and 10 years in blacks; and only
67.4% at both 5 and 10 years in North African patients,
suggesting major differences in prognosis according to
ethnicity (12).
2. Clinical features of Takayasu arteritis
Generally three different phases of TAK are recognized.
In the first phase, there are nonspecific constitutional
inflammatory symptoms. During this phase, TAK may
even present as fever of unknown origin. In the second
phase, mural inflammation starts in the large arteries,
causing carotidynia perceived as neck pain and sometimes
additional thoracal and dorsal pain. The third phase
represents the late phase, characterized with decreased
or absence of pulses and/or differences in arterial blood
pressure between upper extremities, arterial bruits, and
intermittent extremity claudication. The complete form
of TAK may also be divided into two overlapping phases.
While the acute phase represents systemic and initial
vascular inflammation, the occlusive phase, which occurs
weeks to years later, is characterized by ischemic symptoms
(4,13–15). During the course of TAK, occurrence of new,
severe ischemic, vascular manifestations is quite common
compared to other systemic vasculitides, as reported by
Grayson et al. (16). Severe hypertension in TAK may be
caused by atypical coarctation of the aorta, loss of vascular
compliance, aortic valve regurgitation due to aortitis, or
renal artery stenosis. Stroke, transient ischemic attack,
and sudden blindness may also be caused by thrombosis
of cerebral arteries (13–15,17). Erythema nodosum is
reported as the most common skin lesion in TAK in
Caucasian populations (17,18).
Although involvement of the aorta and its main
branches is part of the definition of TAK, it should be
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noted that this involvement is not homogeneous in all
patients with TAK. Rather, there are different types of
involvement, and initial clinical findings may be different
based on the location and extent of vessel involvement.
The most widely used classification of TAK is based on
conventional angiographic findings, as reported at the
International Conference on TAK in 1994. According to
this classification there are six different types of vessel
involvement in TAK (19):
• Type I involves the branches of the aortic arch;
• Type IIa involves the ascending aorta, aortic arch, and
branches of the aortic arch;
• Type IIb involves the thoracic descending aorta with
the involvement of Type IIa;
• Type III involves the thoracic descending aorta,
abdominal aorta, and/or renal arteries;
• Type IV involves the abdominal aorta and/or renal
arteries;
• Type V is the combination of Type IIb and Type IV.
3. Diagnosis of Takayasu arteritis
Currently there are no universally accepted diagnostic
criteria for systemic vasculitides, including TAK. Rather,
there are classification criteria, originally defined to classify
patients who were already diagnosed with vasculitis, for
including these cases in certain clinical trials (20). The
most widely used vasculitis classification criteria are the
American College of Rheumatology (ACR) criteria, which
were defined in 1990 (21). The ACR criteria for TAK consist
of: 1) age of onset before 40 years old; 2) claudication of an
extremity; 3) decreased brachial artery pulse; 4) a difference
of more than 10 mmHg systolic pressure between two
limbs; 5) a bruit over subclavian arteries or the aorta;
and 6) angiographic evidence of narrowing or occlusion
of the aorta, its primary branches, or large arteries in the
proximal upper or lower extremities. The presence of three
of the six criteria is required for differentiating TAK from
other systemic vasculitis.
There is also another set of diagnostic criteria (20)
for TAK, proposed by the Japanese Research Committee
on Vasculitis Syndromes, which include: 1) angiographic
evidence of narrowing or occlusion of the aorta, its
primary branches, or large arteries in the proximal upper
or lower extremities by digital subtraction angiography
(DSA), CT, or MRI; 2) early age of onset; 3) presence of
markers of inflammation; and 4) exclusion of patients
with atherosclerosis, inflammatory abdominal aortic
aneurysm, vascular Behçet’s syndrome, syphilitic aortitis,
giant cell arteritis (GCA), congenital vascular abnormality,
and mycotic aneurysm.
Unfortunately the ACR 1990 criteria generally cover
cases of TAK in the late stage, where it is not difficult
to make the diagnosis. In the context of typical clinical
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symptoms and physical findings such as loss of pulses and/
or decreased arterial blood pressure, and elevated acute
phase responses, various vascular imaging methods may
easily confirm the diagnosis of TAK. In the ACR 1990
criteria for TAK, the only vascular imaging modality
included is conventional radiographic angiography or
DSA (21).
Early diagnosis of TAK in the first or second stages is
the real goal, but difficult to establish. Firstly, the clinician
should remember the possibility of this disease in suspected
cases. There are nine red flags that may alert a clinician
to investigate TAK in a young patient with unexplained
systemic inflammation, as shown in Table 1 (6). In our
opinion, erythema nodosum may also be included among
those red flags.
Another point to be considered in the early diagnosis
of TAK is that initial clinical findings may be different in
different types of TAK. For example, involvement of renal
arteries is prominent in type IV TAK, which may lead
to the presence of HT more frequently and as an early
finding. Type IV is seen more commonly in India and
other South Asian countries; therefore, recent onset of HT
in the presence of systemic inflammation may implicate a
possible diagnosis of TAK in those countries (22).
Whenever the possibility of TAK comes to the mind of
the clinician, the diagnosis of TAK should be confirmed
by the imaging methods discussed and compared with
each other in the following section. Overall, narrowing
or occlusion of the aortic arch and proximal parts of its
branches is highly suggestive of the late stages of TAK.
Involvements of subclavian arteries, especially the left
side, and of common/internal carotid arteries are typical
for TAK. Cluster analysis also revealed that TAK lesions
mostly develop in a symmetric manner in paired vascular
territories and disease extension is contiguous in the aorta
(3,23).
3.1. Use of imaging methods in the diagnosis and followup of patients with Takayasu arteritis
DSA is a useful imaging method not only for the diagnosis
but also for the assessment of the extent and localization

Table 1. Red flags to investigate Takayasu arteritis in a young
patient with otherwise unexplained systemic inflammation.
Carotidynia
Hypertension
Angina pectoris
Vertigo and syncope
Extremity claudication
Absent/weak peripheral pulses
Discrepant blood pressure in the upper limbs (>10 mmHg)
Arterial bruits
Aortic regurgitation

of vascular involvement in TAK. DSA may detect arterial
stenoses, occlusions, and aneurysms in large and mediumsized vessels. However, DSA only visualizes the lumen
of the vessel, without giving any information about the
vessel wall. DSA may miss minor, nonocclusive lesions
and also does not have adequate resolution for small
vessels. Besides, it is an invasive method causing exposure
to contrast media and radioactivity (24–26). It should be
noted that DSA is no longer the gold standard for diagnosis
of TAK (8,25,27).
Currently, many physicians prefer to use magnetic
resonance angiography (MRA) or computerized
tomography angiography (CTA) for establishing the
diagnosis of TAK. MRA and CTA are helpful for the
evaluation of the aorta and its primary branches. CTA
may provide excellent anatomical characterization of
structural changes in the aorta, but may not detect early
disease activity (28). Although MRA can show vessel wall
thickening, edema, and contrast enhancement, (29), it
has been shown that correlation with clinical activity or
systemic inflammation is poor and it is shown to have a
limited role for long-term follow-up (30,31).
On the other hand, color Doppler ultrasonography
(CDU) is helpful to evaluate temporal, carotid, axillary,
and femoral arteries, but it fails to depict the thoracic
aorta unless performed as a transesophageal examination.
Similar to MRA and CTA, CDU can not only visualize
luminal changes, stenoses, and aneurysms of large arteries;
it can also detect the characteristic homogeneously
thickened vessel walls, as well as mural inflammation
and edema, which are early inflammatory signs. CDU
also provides better resolution than MRA and CTA (26).
There is no risk of radiation exposure in MRA and CDU.
Disadvantages of MRA include overestimation of vascular
occlusions and inability to visualize small branch vessels
and vascular calcifications.
Positron emission tomography (PET) with
18F-fluorodeoxyglucose (18F-FDG PET) is a noninvasive
imaging method that measures 18F-FDG, which
accumulates in hypermetabolic, activated inflammatory
cells infiltrating the vessels. On the other hand, 18F-FDG
PET/CT combines the functional information from PET
and the anatomical information from CT. 18-FDG-PET
is the most sensitive test for early vessel inflammation.
Therefore, both early vascular inflammation and its
location in the aorta and its branches may be detected
using PET-CT in the first two phases, which may help in the
early diagnosis of TAK. However, vascular uptake on PET
is not specific for vasculitis, and discriminating between
atherosclerotic and vasculitic lesions may be challenging.
Unfortunately, PET cannot delineate the vessel wall
structure and luminal flow; besides, the radiation exposure
is high, particularly in PET-CT (32–34). A metaanalysis
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of six studies with 18-FDG-PET reported its sensitivity as
70.1% and specificity 77.2%, with a moderate diagnostic
value (35).
In summary, MRA, CTA, CDU, or in selected cases
18F-FDG PET-CT may be helpful in the early diagnosis
of TAK, before the narrowing of the vessel lumen;
unfortunately, this is not possible with DSA.
4. Genetics of Takayasu arteritis
Although the etiology of TAK is still unknown, genetic
factors clearly contribute to pathogenesis (36).
Some major progress in understanding the
pathogenesis of TAK came with the first two genome-wide
association studies (GWASs) from Turkey/the United
States and Japan, demonstrating the role of HLA-B*52 and
single nucleotide polymorphism associations with IL-12B
and FCGR2A/3A (37–39). FCγR2A/3A association is also
shown in the Chinese population (40). Interestingly, IL12B is also shown to be a common genetic component
between GCA and TAK (41).
In the recent larger GWAS study, new genetic
susceptibility loci for TAK with a genome-wide level of
significance in the IL6 gene (odds ratio [OR] = 2.07),
RPS9/LILRB3 (OR 1.65), and an intergenic locus on
chromosome 21q22 (OR = 1.79) were also demonstrated
(42). The genetic susceptibility locus in RPS9/LILRB3 lies
within the leukocyte receptor complex gene cluster on
chromosome 19q13.4, and the disease risk variant in this
locus correlates with reduced expression of multiple genes
including the inhibitory leukocyte immunoglobulinlike receptor gene LILRB3. In addition, other candidate
susceptibility genes with suggestive levels of association
with TAK, including PCSK5, LILRA3, PPM1G/NRBP1,
and PTK2B, were also shown in this study. In the largest
ever genetic study of different vasculitides including large
and medium vessel types, the strongest association signal
corresponded with an intergenic polymorphism located
between HLA-DQB1 and HLA-DQA2 (OR = 0.74). This
single nucleotide polymorphism is in moderate linkage
disequilibrium with the disease-specific human leucocyte
antigen (HLA) class II associations of each type of
vasculitis and could mark them. Outside the HLA region,
the KDM4C gene was identified as a common risk locus
for vasculitides (OR = 1.75). This gene encodes a histone
demethylase involved in the epigenetic control of gene
expression (43).
5. Immune pathogenesis of Takayasu arteritis
Other than genetic factors, infectious agents are also
accepted to contribute to the pathogenesis of TAK
(44). Whatever the exact triggering factors are, a cellmediated immune response is triggered, as also suggested
by histological findings showing inflammatory cell
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infiltrations and necrosis of the arterial vascular wall (45–
47). Vascular inflammation of TAK possibly originate in
the vasa vasorum, followed by infiltration of inflammatory
cells with the production of inflammatory and Th1type cytokines, such as tumor necrosis factor (TNF)-α,
interferon (IFN)-γ, interleukin (IL)-12, and IL-18, leading
to the formation of granulomas (48). Th17 cells induced
by IL-6 and IL-23 in the microenvironment possibly also
contribute to the vascular lesions through the recruitment
of infiltrating neutrophils (49). IL-12/IFN-γ-associated
Th1 and IL-6-IL-17 and IL-23-dependent Th17 pathways
are more clearly defined in GCA, a similar large vessel
vasculitis. In recent studies, increased B-cell aggregates are
also shown in the adventitia of the aorta in TAK patients,
suggesting that B-cell depletion therapy might also have
value in treatment (50,51).
In a search to find better biomarkers for disease
assessment, in various previous studies, serum
concentrations of IL-6, RANTES (regulated on activation,
normal T cell expressed and secreted), IL-8, IL-12, and IL18 were studied and some appear to correlate with disease
activity (52–56). Matrix metalloproteinase-9 and recently
pentraxin3 (PTX-3) have also been suggested to be related
to active disease in TAK; however, these data require
confirmatory studies (57,58).
IL-6 is a proinflammatory cytokine mainly synthesized
by activated monocytes, macrophages, and T cells and
has an important role in the Th17 pathway. Serum IL-6
levels have been shown to be raised in active GCA and
TAK patients, correlating with disease activity (59). IL-6
receptor blockage also seems to be the most promising
new treatment option for large vessel vasculitides. IL23 is a member of the IL-12 family, which is important
for the generation and maintenance of Th17 cells. IL-23
has been associated with the generation of a particularly
proinflammatory subset of Th17 that expresses both IL17 and IFN-γ. Serum IL-23 levels were similar to those
of healthy controls in patients with TAK. However, IL23 levels stayed high in inactive disease, suggesting that
it might be a factor for disease relapses, similar to the
observations in GCA (58,60).
Antiendothelial cell antibodies and the mammalian
target of rapamycin (mTOR) pathway were also reported to
contribute to vascular inflammation in TAK. Higher levels
of serum antiendothelial cell antibodies were detected in
TAK patients compared to controls. The activation of both
mTORC1 and mTORC2 specifically in endothelial cells
from TAK patients was also shown (61,62).
6. Systemic inflammation versus vascular wall
inflammation in Takayasu arteritis
Systemic inflammatory response does not always show
a positive correlation with inflammatory activity in the
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vessel wall. Therefore, TAK may be active despite normal
erythrocyte sedimentation rate (ESR) and serum CRP
levels, and vice versa (63). In patients with apparent clinical
and laboratory remission, arterial specimens may show
histological signs of vasculitis (4,63). Recently it has been
shown that there are clear discrepancies between these
two types of inflammation, including cytokine patterns
and even responses to treatment. Although no definite
boundaries exist, it may be suggested that the IL-6/Th17/
IL-17 pathway primarily drives systemic inflammation,
while the IL-12/Th1/IFN-γ pathway dominates in vascular
wall inflammation not only in TAK but also in GCA
(48,64). Corticosteroid (CS) and immunosuppressive (IS)
treatments initially suppress systemic inflammation, while
longer treatment duration is required for the suppression
of vascular inflammation. Therefore, evaluating only the
systemic inflammation may be misleading. Vascular wall
inflammation is currently evaluated using expensive
imaging methods that are not feasible for repetitive use.
Although PTX-3 is superior to ESR and CRP, we need more
reliable biomarkers to reflect vascular wall inflammation
in patients with TAK. However, identifying these
biomarkers is very challenging and may be accomplished
only by means of prospective, multicenter studies utilizing
repetitive imaging together with serial serum samples for
biomarker studies in a cohort of newly diagnosed TAK
patients (48).
7. Assessing disease activity in Takayasu arteritis
Due to the discordance between systemic and vascular wall
inflammation in TAK, in clinical practice, suppression of
vascular inflammation is generally evaluated by imaging
methods, especially MRA. On the other hand, monitoring
overall disease activity in TAK may be accomplished by the
integrated use of noninvasive imaging methods, patient
symptoms, clinical findings, and acute phase reactants
(27). There is no single imaging modality that can provide
all the information required and each method has distinct
and complementary roles in monitoring (25).
To identify effective new biomarkers, we need
inflammatory molecules that are locally produced at sites of
vascular inflammation, which are expected to better reflect
the degree of vascular wall inflammation. Since PTX-3 is
involved in the maintenance of vascular homeostasis (65),
measuring plasma levels of PTX-3 was suggested as a
more reliable and promising biomarker to reflect vascular
disease activity in TAK (58,66,67). Tombetti et al. showed
that PTX-3 may identify vascular progression only in
a subgroup of TAK patients not receiving anticytokine
treatments, while levels of CRP more accurately reflected
the burden of systemic inflammation. However, in other
patients with TAK, including those receiving anticytokine
treatments, even plasma PTX-3 levels were shown to be

normal despite ongoing smoldering vascular inflammation
(66). In other words, although PTX-3 certainly had some
advantages compared to CRP, it unfortunately could not
solve the problem of detecting smoldering vascular wall
inflammation in TAK.
In the literature, there are criteria defined for assessing
disease activity in TAK. According to the Kerr criteria
(4), the presence of recent occurrence or deterioration
of at least two of the following four criteria shows active
disease: 1) systemic features like fever and arthralgia that
cannot be explained by other reasons; 2) elevated ESR; 3)
findings of vascular ischemia and inflammation; and 4)
typical angiographic findings.
The Disease Extent Index Takayasu (DEI.Tak) was
defined in 2005 for the follow-up of TAK by assessing
only new clinical findings within the past 6 months
without a requirement for imaging techniques or acute
phase reactants (68). DEI.Tak was created using BVAS
as a template and included 71 items. The items directly
related to large arterial disease including stenosis and
claudication were weighted for scoring more than general
items of disease (e.g., fever, fatigue), aiming to give more
importance to cardiovascular findings. The DEI.Tak was
shown to be a practical and valuable tool to assess disease
activity and progression in a Turkish TAK series (69).
Recently, the Indian Takayasu Clinical Activity Score
(ITAS2010) was published as a disease activity score for
TAK (70). The ITAS2010 has only six systems and, similar
to DEI.Tak, scoring was also weighted for vascular items.
The ITAS2010 only evaluates the clinical features of the
disease occurring during the prior 3 months, assessed
by a physician; however, evidence of blocked vessels
documented by vascular imaging for determining pulse
losses is also included (8,70,71). The ITAS2010 seems
to have a good comprehensiveness and the interrater
agreement seems better than a physician’s global
assessment (PGA) (0.97 vs. 0.82) (8). Misra et al. also made
a further attempt to incorporate acute phase responses
into the score by adding an extra 1–3 points for elevated
ESR or CRP, thus creating the ITAS2010-A. However,
ITAS2010-A scores were found to be higher both in active
and inactive patients. In other words, ITAS2010-A scores
may remain high even in patients responding to treatment
and being accepted as clinically inactive according to the
PGA. Although the authors suggested an ITAS2010 score
of 4 points as a cut-off to separate active and inactive
disease, the presence of ITAS2010 items during apparent
remission is an important problem, and there is substantial
difficulty in differentiating current TAK activity from
damage due to problems not related to vasculitis (8).
Physical examination for new vascular signs was accepted
as the major tool in the ITAS2010. However, there are also
limitations of physical examination, as recently shown by
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Grayson et al. (72). The authors compared physical signs
with imaging data and reported that individual physical
examination findings had poor sensitivity (14%–50%)
and at least 30% of the lesions detected by imaging were
missed. Therefore, clinical assessment should be combined
with acute phase responses and new imaging findings to
assess current disease activity.
8. Similarities and differences between Takayasu
arteritis and giant cell arteritis
There is an ongoing debate concerning whether TAK
and GCA may represent a spectrum of the same disease
(64,73,74). Similarities of these two diseases may be
summarized as the common role of cell-mediated immunity
in their pathogenesis, similar pathological findings in the
vessel wall, and high serum levels and vascular expressions
of certain cytokines including IL-6 and IL-17. Recently, a
metachip analysis including both GCA and TAK patients
revealed IL-12B as the most prominent genetic factor for
both diseases (41).
On the other hand, there are striking differences
between GCA and TAK, including age of onset, ethnic
discrimination, clinical features, and vascular distribution.
While TAK is generally seen in young females from Far
Eastern and Asian countries, GCA is generally seen in older
patients especially of Caucasian origin. Unlike TAK, which
tends to affect branches of the internal carotid artery, GCA
has a tendency to affect branches of the external carotid
artery. Therefore, headache, jaw or tongue claudication,
and scalp tenderness are not expected to occur in TAK,
unlike stroke, which is more common in TAK compared
to GCA. Although involvement of the aorta and its main
branches is more typical for TAK, it should be noted that
there is a subgroup of GCA presenting in this way, without
cranial arteritis, as discussed above (64,73,74).
Grayson et al. investigated the distribution of arterial
lesions in two North American cohorts consisting of
145 patients with TAK and 62 patients with GCA (3).
Cluster analysis demonstrated that arterial involvement
was contiguous in the aorta and usually symmetric in
paired branch vessels both for TAK and GCA. They
reported that carotid and mesenteric arterial diseases were
seen more frequently in TAK, and axillary disease was
more frequent in GCA. While subclavian involvement
tended to be asymmetric in TAK with a high frequency
of left subclavian artery disease, symmetric subclavian
with concomitant axillary involvement was seen more
frequently in GCA. However, cluster analysis of arterial
involvement could not show differences between TAK
and GCA in 56% of patients. Given that there are strong
similarities but also subtle differences in the distribution
of arterial disease between TAK and GCA, these authors
suggested that TAK and GCA might exist on a spectrum
within the same disease (3).
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The types of cytokines primarily suppressed by CS
treatment, i.e. cytokine response patterns, are also different
in TAK and GCA. In patients with TAK, serum levels of
Th1 cytokines are easily suppressed, while Th17 cytokines
are resistant (49,64). On the other hand, in patients with
GCA, the Th17 pathway is rapidly suppressed, while the
Th1 pathway (IFN-γ production) is relatively CS-resistant
and responsible for ongoing vascular inflammation (75,76).
TNF inhibition may also be effective in the treatment of
TAK (77,78), while it remains relatively ineffective in GCA
(64,79).
9. Differential diagnosis between Takayasu arteritis and
atherosclerosis
Various pathologies may cause narrowing of the lumen
in the aorta and its branches. Among those mimickers,
atherosclerosis is probably the most commonly
encountered pathology, and differentiating atherosclerotic
lesions from vasculitic lesions, especially in older patients
with TAK, is not always easy. Furthermore, there is a
well-known association between inflammation and
atherosclerosis, which may result in the presence of both
vasculitic and atherosclerotic lesions in TAK (80). Given
that atherosclerosis is also an inflammatory process,
atherosclerotic plaques may also cause increased uptake of
gadolinium contrast in MRA and increased FDG uptake
in PET-CT imaging, resulting in further confusion (81).
Practical points helpful in differentiating these lesions
include the following (80,82,83):
• Atherosclerotic lesions tend to be localized in
bifurcation sites and in ostia in isolated atherosclerosis,
while they are generally located on proximal parts of the
arteries in TAK.
• Traditionally, atherosclerosis is a major risk factor
especially for abdominal aortic aneurysms, while TAK
may cause both thoracal and abdominal aortic aneurysms.
• The arteries of the upper limbs are rarely involved in
atherosclerosis, which is helpful in differential diagnosis.
• Coronary calcifications are typical for atherosclerosis,
rather than TAK.
• Atherosclerosis causes localized, nonhomogeneous,
and irregular mural thickening, while TAK causes diffuse
and homogeneous arterial vessel wall thickening.
• In PET-CT imaging, atherosclerotic lesions of the
aorta are generally seen as localized hot spots, while
vasculitic lesions may be seen as linear smooth PET signals.
• Using CDU, atherosclerotic lesions usually present
with localized thickening of the intima-media complex,
while the presence of dark hypoechogenic circular vascular
wall thickening around the femoral arterial lumen, the socalled halo or macaroni sign, suggests the diagnosis of
vasculitis. Concentric, smooth thickening of the arterial
vessel wall, leading to long-segment stenosis, is also typical
for lower limb vasculitis.
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• Using MRA, increased vessel wall thickness of the
large arteries with linear mural contrast enhancement on
T1 sequences and vessel wall edema on T2 sequences may
suggest the diagnosis of vasculitis.
• Using CTA, calcifying plaques may be visualized,
which can distinguish between atherosclerotic and
inflammatory lesions.
• Punctate, linear calcifications and discrete plaque
lesions and patchy involvement suggest atherosclerosis,
whereas mural and circumferential calcifications with
uniform and diffuse involvement suggest TAK.
10. Management of Takayasu arteritis
For optimum management of TAK, the pattern and extent
of arterial involvement as well as current disease activity
should be known. Patient education, cooperation between
the doctor and the patient, and supportive measures should
not be ignored. Although the rationale of the management
is to suppress both vascular and systemic inflammation
with medical treatment, endovascular interventions
and/or surgical procedures may be also tried in selected
cases with critical arterial stenosis. However, as a general
rule, such interventions should be avoided during the
active phase of the disease and should be tried only after
suppression of vascular inflammation by appropriate IS
treatment (84).
CSs are almost always the initial treatment, and
conventional second-line IS agents such as methotrexate
(MTX), azathioprine (AZA), mycophenolate mofetil
(MMF), and leflunomide (LEF) are generally used alone or
in combination to facilitate tapering the CS dose. Because
of well-known potential adverse effects including gonadal
toxicity, cyclophosphamide (CYP) is reserved for severe
complications, as discussed in the following paragraphs.
For patients resistant to these agents, i.e. for those
with refractory disease, biologic agents including TNF
inhibitors (TNFi), tocilizumab (TCZ), rituximab (RTX),
and abatacept (ABA) may be added (27,85).
Before discussing the available evidence for each of
these therapeutic agents, it should be stressed that, as
with many other orphan diseases, the level of evidence for
management of TAK is rather low. Except for a recently
completed placebo-controlled randomized trial (86), most
of the available data reflect the results of open studies,
case series, and expert opinion. Therefore, currently it is
not known whether a single conventional IS agent is more
effective than others. Besides, there are no widely accepted
criteria for definition of refractory disease activity to decide
which patients warrant appropriate biologic treatment. In
this regard, the Turkish Takayasu Arteritis Study Group
issued a definition of refractory disease as shown in Table
2 (27,38,85).

10.1. Supportive measures
Although CS treatment is quite effective in TAK, metabolic
side effects are important problems. Diet, low salt intake,
calcium and vitamin D supplementation, and regular exercise
are essential to reduce CS-related side effects. Monitoring
and control of blood pressure may be difficult for patients
with absent or reduced pulses in some extremities. Blood
pressure measurements should be made in the unaffected
extremities, including the lower extremities if necessary. In
some patients with unreliable measurements, hypertensive
retinopathy should be investigated as a warning sign for
the clinician.The possibility of renovascular hypertension
should be considered in the presence of treatment-resistant
hypertension. In such cases, endovascular interventions
or surgery may be necessary (27). Similar to other
inflammatory diseases, the risk of atherosclerosis is also
increased in patients with TAK (80). Therefore, preventive
measures including use of antiplatelet agents should be
considered. In the literature, there are a few studies favoring
the use of antiplatelet agents in TAK (87–89). Furthermore,
Numano et al. showed that antiplatelet therapy was
associated with a lower frequency of ischemic events in
patients with TAK (90). However, the relative efficacy of this
treatment between different angiographic stages of TAK is
not known (91).
10.2. Corticosteroids
In the presence of active disease, standard initial CS
treatment is high-dose (1 mg/kg daily) prednisolone or its
equivalents. Generally, two-thirds of the total daily dose
is given early in the morning and the rest of the dose in
the evening after meals. The response to high-dose CS is
generally favorable, but relapses may occur while gradually
tapering the dose. Besides, adverse effects of long-term
treatment are devastating. Therefore, many physicians,
including us, tend to start conventional IS agents together
with the initial CS treatment or while tapering the CS dose
(27,92,93).
10.3. Methotrexate
Since MTX is an inexpensive, easily available, and relatively
safe agent that is widely used in rheumatology, it is the first
choice of many physicians. However, data regarding MTX
use in TAK are limited, consisting of case reports and a
few small open studies (94–99). The most important data
about the use of MTX in TAK come from the open study
performed by Hoffman et al. in 1994 (98). They reported 16
patients with TAK given standard CS treatment plus MTX.
Thirteen patients (81%) went into remission and eight
patients (50%) remained in remission for a mean period of
18 months.
10.4. Azathioprine
AZA is another IS agent widely used for the treatment
of TAK. Besides case reports (100,101), there is only one
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Table 2. Definition of refractory disease in Takayasu arteritis as suggested by the Turkish Takayasu arteritis study group.
Angiographic or clinical progression despite treatment or the presence of any of the following characteristics
Prednisolone dose >7.5 mg/day after 6 months of treatment, despite administration of conventional IS agents;
New surgery due to persistent disease activity;
Frequent attacks (more than three per year); and
Death associated with disease activity.

open study from India (102). In this study, 65 IS agentnaive patients with TAK were given 2 mg/kg AZA daily in
addition to CS treatment for 1 year. At the end of the first
year, acute phase responses were significantly reduced, no
adverse events occurred, and control angiography showed
no progression. However, long-term follow-up of these
patients was not reported.
10.5. Cyclophosphamide
CYP is a very potent and effective IS agent. In TAK, CYP
is generally used in the presence of severe life- and/or vital
organ-threatening conditions, including retinal vasculitis,
pulmonary artery involvement with or without aneurysm,
severe aortic regurgitation, or myocarditis, as reported in
the literature (103–106). In a prospective study performed
of TAK, seven patients resistant to CS treatment were
additionally given 2 mg/kg oral CYP daily (106). After a
mean period of 27.5 months, no clinical or radiological
progression was observed in these patients. With respect
to adverse events, hemorrhagic cystitis developed in
two patients, herpes zoster in one, and oligomenorrhea
in seven. In another open study, eight patients with
TAK having myocardial involvement were reported to
experience clinical hemodynamic and morphological
improvement using CS plus CYP treatment (107).
10.6. Mycophenolate mofetil
MMF is a promising agent in TAK. Three patients with
TAK, resistant to CS plus MTX, were given MMF treatment
(2 g/day) for at least 1 year with favorable clinical and
radiological response (108). In the first open MMF study,
10 patients with treatment-resistant TAK were given MMF
for a mean period of 23 months, resulting in significant
reductions in acute phase proteins (109). Goel et al.
reported the data of 21 consequent Indian TAK patients
using MMF for 9.6 ± 6.4 months (110). Among those
patients, 10 had been resistant to CS plus AZA treatment.
Using the ITAS and PGA, improvement in disease activity
was shown. CS requirement was also reduced. The only
adverse event reported was skin rash in a single patient.
This study is notable for showing favorable efficacy and
safety profile for MMF treatment in TAK.
10.7. Cyclosporine and tacrolimus
Known as calcineurin inhibitors, CSA (111–113) and
tacrolimus (114) were also tried in selected cases of
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TAK with successful results. It has also been shown that
CSA may be effective in the treatment of pyoderma
gangrenosum complicating TAK (112,113,115).
10.8. Leflunomide
LEF is a promising agent for TAK treatment. In addition
to case reports of LEF use in TAK with promising results
(116,117), the effectivity of LEF in treatment-resistant
active disease was also shown in a prospective open-label
study (118). In this study, 15 patients with TAK were given
20 mg of LEF daily. Disease activity was evaluated by
Kerr’s criteria and by the ITAS2010. Not only the shortterm results of a mean follow-up of 9.1 months but also
the long-term results of a mean follow-up of 43.0 months
showed a favorable clinical response (119). Among 15
patients, follow-up information was available for 12
patients for the long-term report. While five (41.6%) TAK
patients remained on LEF therapy, seven (58.3%) TAK
patients had to switch to another therapy due to relapses in
disease activity in six patients and toxicity in one patient.
10.9. Tumor necrosis factor inhibitors
Given that vascular inflammation in TAK is granulomatous
and vascular expression of TNF-α is abundant, TNFi agents
are the first biologic agents tried for the treatment of TAK.
Unlike GCA, TNFi agents were found to be effective in
TAK, as reported in multiple retrospective observational
studies (77,78,120). Analysis of 120 patients with refractory
TAK receiving TNFi agents showed that infliximab (IFX)
was the most commonly used agent (80%), while the
remaining patients had used either etanercept (ETA) or
adalimumab (ADA) (121). Overall response rate was 80%,
and the CS dose could be reduced or discontinued in over
40% of the patients. However, relapses occurred in 37%
of patients and nearly 50% of relapsing patients required
either an increase in dose or frequency, or were switched
to a different TNFi agent.
In another study the data of 49 patients with TAK who
used various biological agents from different centers with
a median treatment duration of 16 months (2–85 months)
were retrospectively analyzed. Among those patients,
35 had received TNFi biologics (IFX 28, ETA 6, ADA
1). While 32 patients received TNFi agents as secondline treatment after resistance to conventional IS agents,
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three patients had received these agents as the first-line
treatment. Complete responses were seen in 35%, 61%, and
74% of the patients at months 3, 6, and 12, respectively. No
relapse was observed in three years in 91% of the patients.
However, during follow-up, at least one switch to another
biologic agent was performed in 40% of the patients (122).
In summary, the results of observational studies as
well as our personal experience confirm that TNFi agents
may be beneficial in refractory TAK. Lack of randomized
controlled trials with TNFi agents is an important problem
preventing us from concluding the exact role of these
agents in the treatment of TAK.
10.10. Tocilizumab (TCZ)
Given that IL-6 has a critical role in the pathogenesis
of TAK, TCZ, which is an IL-6 receptor inhibitor, is a
promising agent for the treatment of TAK (123–125).
The clinical efficacy of TCZ in TAK was first reported by
Nishimoto et al. in 2008 (126). Following this initial case
report, many studies reported beneficial effects of TCZ in
patients with TAK having relapsing and refractory disease
(127–133). The majority of the patients reported were
treated with a TCZ dose of 8 mg/kg every 4 weeks, while
a minority of patients were treated with 4 mg/kg every 4
weeks or 8 mg/kg every 3 weeks. In a retrospective analysis
of 44 patients with TAK treated using TCZ, this agent was
reported to be effective in the treatment of TAK in terms
of clinical, biological, and radiological responses. TCZ was
also reported to be a relatively safe steroid-sparing agent
in TAK. TCZ may also be effective as rescue treatment for
TAK patients resistant to TNFi agents (134).
Mekinian et al. (122) also reported 14 TAK patients
who received TCZ, 11 of whom received it as secondline treatment after resistance to conventional IS agents.
The other three patients had received TCZ as first-line
treatment. Mekikian et al. reported that 29% of TAK patients
treated with TCZ required at least one switch to another
biologic treatment, suggesting that primary failure to TCZ
may also be seen. Interestingly, the authors compared
their patients treated with TCZ with those receiving TNFi
agents and found that these two groups of patients were
similar with respect to proportion of responders, vascular
interventions, vascular complications, and relapse-free
survival (122).
Overall, TCZ treatment was reported to be effective
in TAK with more than 80% of patients having clinical
and laboratory response within 3 months. Unfortunately,
some of these patients experienced a relapse during
treatment (85,125). As reported by Goel et al., although all
of the 10 patients with TAK refractory to CS and secondline agents went into remission by the fourth infusion
of TCZ, three patients (30%) relapsed both clinically
and radiographically by the sixth infusion (127). More
importantly, radiographic worsening occurred despite

normalized acute phase responses. This observation of
silent vascular progression despite suppression of systemic
inflammation with TCZ was also reported in other
studies (48,132,133,135). Therefore, while evaluating
clinical response, close monitoring with regular clinical
assessment and serial imaging are obviously necessary
during TCZ treatment (136). Even if some patients with
TAK respond well to TCZ treatment, relapse is frequently
seen at 2–6 months after discontinuation of TCZ (127).
Even cytokine storm was defined after cessation of TCZ
(137). It is unknown whether maintenance therapy with
a conventional IS agent should be started when treatment
with a biologic agent is discontinued.
Recently Nakaoka et al. reported the results of the
first randomized, double-blind, placebo-controlled, phase
3 TCZ trial performed in Japan, the TAKT study (138).
They included 36 patients with TAK who had relapsed
within the previous 12 weeks and gone into remission
with oral CS treatment. These patients were randomly
assigned 1:1 to receive weekly TCZ at 162 mg or a placebo
subcutaneously. Oral CSs were tapered 10% weekly from
week 4 to a minimum of 0.1mg/kg daily until 19 patients
relapsed. The primary endpoint was time to relapse of
TAK, defined as ≥2 of the following: objective systemic
symptoms, subjective systemic symptoms, elevated
inflammation markers, vascular signs and symptoms, or
ischemic symptoms. The per-protocol set (PPS) included
16 TCZ-treated and 17 placebo-treated patients. HRs for
time to relapse of TAK were 0.41 (95.41% CI: 0.15–1.10;
P = 0.0596) in the intent-to-treat population (primary
endpoint) based on relapse in eight TCZ-treated and 11
placebo-treated patients and 0.34 (95.41% CI: 0.11–1.00;
P = 0.0345) in the PPS. The secondary endpoints, time to
relapse assessed by Kerr’s definition and clinical symptoms
only, were consistent with the primary endpoint. There
were no serious infections and no deaths. Although the
primary endpoint was not met in this trial, the authors
concluded that TCZ was superior to the placebo for time
to relapse of TAK without new safety concerns (138).
In summary, although TCZ appears to be effective
and relatively safe in refractory TAK, information on its
use in newly diagnosed patients naive to conventional IS
agents or anti-TNF therapy is limited. Another phase III,
open-label study evaluating the use of TCZ as first-line
treatment in TAK is currently underway (ClinicalTrials.
gov identifier: NCT02101333).
10.11. Abatacept (ABA)
Assuming that inhibiting T-cell activation by means of
blocking costimulatory signals may be helpful, abatacept
was also tried in the treatment of TAK (139). However,
case reports showing efficacy of ABA in patients with TAK
are rare (139). A multicenter clinical trial that evaluated
the efficacy of ABA concurrently for GCA and TAK was
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also performed. Unfortunately, the results for TAK were
disappointing. Treatment with ABA combined with
prednisone did not provide a longer duration of relapsefree survival when compared to treatment with prednisone
alone (86).
10.12. Rituximab
Although TAK is accepted primarily as a T-cell-mediated
disease, dysregulation of B-cell homeostasis was also
suggested to contribute to its pathogenesis. Presence of
both T and B cells was shown in the inflamed arterial
adventitia of aortic wall samples from patients with TAK
(140–142). Interestingly, while naive B cells are decreased,
circulating newly generated plasmablasts and memory B
cells are increased in patients with active TAK compared
to inactive and control patients (142). Therefore, RTX,
which is a chimeric anti-CD20 monoclonal antibody, was
also tried in TAK (143,144). In the literature, there are
case reports of RTX treatment in patients with refractory
TAK who had not responded to conventional IS agents
and/or TNFi biologics (142,145,146). RTX was generally
used according to the protocol established for rheumatoid
arthritis (1000 mg at days 0 and 15). RTX treatment was
reported not only to result in clinical remission but also
to reduce the expansion of newly generated plasmablasts
in TAK cases (142). There are also case reports and
suggestions for the use of RTX in TAK as a first-line IS
agent (144,147). Recently, Pazzola et al. reported the
results of seven TAK patients treated with RTX. While
six patients had refractory disease, there was also a single
newly diagnosed, treatment-naive TAK patient who had
refused CS treatment and received RTX alone as a firstline IS agent. The authors concluded that RTX might have
a role in some treatment-resistant TAK patients as secondor third-line biologic therapy, rather than as the first-line
biologic therapy (51).
10.13. Endovascular interventions and surgery
In the chronic stages of TAK, where there are persistent
lesions that cannot be reversed by suppression of
inflammation with medical treatment, endovascular
interventions or surgery may be tried. If the problem is
severe ischemia of any affected organ or extremity, such
as hypertension caused by severe renal artery stenosis,
cerebrovascular ischemia, coronary artery ischemia, or
limb claudication, revascularization either by surgery or
endovascular interventions including balloon angioplasty,
stent, and stent graft replacement may be helpful (148–
151). As a general rule, both endovascular interventions
and surgery should not be performed during active
disease. In other words, such procedures should be tried
after suppressing systemic and vascular inflammation
(148,149).
The success rate and outcome of endovascular
interventions obviously depend on the site, length, and
stage of the arterial stenosis. In the presence of short-
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segment, critical arterial stenosis, balloon angioplasty
or stent graft replacement may be useful. Percutaneous
transluminal angioplasty is a less invasive and safe
method; however, restenosis may occur in up to 77.3%
of the procedures in the long term (152–154). If there is
long-segment stenosis with extensive periarterial fibrosis
or occlusion, surgical bypass of the affected segment is the
procedure of choice and is clearly associated with superior
results compared with endovascular interventions. The
superiority of arterial surgical bypass reconstruction has
been reported especially for lower limb and renal arteries
(148–151,155).
Unfortunately, in-stent stenosis is an important
complication. External stent compression by progressive
vessel wall fibrosis and calcification was suggested to
contribute to this complication (153,154,156). Although
drug-eluting balloons and/or stents were offered to avoid or
to minimize this complication, this topic is controversial.
The use of drug-eluting systems may be useful to prevent
intramural inflammation and severe intimal hyperplasia.
Recently, Kazibudzki et al. reported a complicated case
of TAK successfully treated with a drug-eluting balloon
before stent implantation in the common carotid artery.
According to these authors this strategy gave a higher
probability of restenosis avoidance (154). However, there
are also reports suggesting that such stents may increase
the risk of early and late in-stent thrombosis (153,154,156).
On the other hand, antiplatelet treatment may not only
lower the frequency of ischemic events in TAK (90) but also
may decrease the likelihood of restenosis development,
based upon the experience acquired from coronary
interventions (157). Therefore, at least 6 months of dual
antiplatelet therapy (27,157) as well as postinterventional
IS treatment (158) are recommended to increase the
success of endovascular interventions.
Other than bypass surgery for revascularization, other
possible surgical indications for patients with TAK include
progressive aneurysm enlargement having the tendency
for dissection or rupture, moderate to severe aortic
regurgitation, and severe aortic coarctation.
11. Prognosis of Takayasu arteritis
We believe that the duration and severity of both systemic
and vascular inflammation, as well as major complications
resulting from the vascular lesions, are important
factors for prognosis. Late diagnosis and progressive
disease course resistant to treatment may also cause
poor prognosis. The presence of Takayasu retinopathy,
renovascular hypertension, aortic regurgitation, aortic
aneurysm, and/or comorbidities mostly resulting from
CS treatment may also contribute to poor prognosis in
TAK. In an old study performed in Japan for calculating
15-year survival rates in TAK, patients were stratified
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based on three different parameters, namely presence or
absence of a major complication, presence or absence of
progressive disease course, and age at diagnosis (159). The
reported 15-year survival rates were 66.3% vs. 96.4% for
patients with and without a major complication, 67.9% vs.
92.9% for patients with and without a progressive course,
and 58.3% vs. 92.7% for age >35 years vs. ≤35 years,
respectively. Common causes of death in TAK include
acute myocardial infarction, congestive heart failure,
cerebrovascular accident, renal failure, and aneurysm
rupture (15,160). In a recent study, reflecting the results of
a large series with a long follow-up from the Mayo Clinic,
USA, overall survival was much better compared to earlier
series (97% at 10 and 86% at 15 years), although mortality
was still increased compared to the general population
(161). Similarly, Ohigashi et al. suggested that prognosis
of TAK had improved over the last decade. Based on an
analysis of 106 patients, they reported mortality of TAK as
2.8% during the 2000–2010 follow-up period (162).
Differences of mortality rates reported in different
series may be explained by diverse disease phenotypes and
severities due to ethnicity. Differences in medical therapy
(e.g., less or more frequent use of CSs and cytotoxic
agents) and variations in access to endovascular or surgical
therapy may also affect the mortality rates (8).

12. Conclusion
Although TAK is a challenging disease, increased
awareness among physicians as well as the combination
of careful physical examination, assessment of acute
phase responses, and use of appropriate imaging studies
may be helpful for early diagnosis. Discrepancies between
systemic and vascular wall inflammation should always
be kept in mind while assessing disease activity. There
are current attempts to define better outcome measures
for TAK. Combining new clinical features, acute phase
responses, and the information from serial noninvasive
imaging seems to be the most logical approach for
assessing response to treatment and current disease
activity. The rationale of medical treatment is to suppress
inflammation with CSs and conventional IS agents. In
cases of refractory disease activity, LEF, TNFi agents,
and TCZ may be tried. In selected cases with persistent
lesions that cannot be reversed with medical treatment,
endovascular interventions including balloon angioplasty,
stent and stent graft replacement, or surgery may be tried.
However, such procedures should be performed after
suppression of inflammation. The prognosis of TAK is
probably getting better with lower mortality rates reported
in recent years, probably due to the use of more effective
medical treatments as well as the use of endovascular
interventions when necessary and available.
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